Skip to content
Cost Savings

GLP-1 Cash-Pay Guide for 2027: What to Pay When Employer Coverage Drops

7 min readBy Jeremy H., GLP-1 Nutrition Researcher
GLP-1 Cash-Pay Guide for 2027: What to Pay When Employer Coverage Drops

How we check prices: our medication-cost methodology explains the sources behind the figures in this guide. Prices checked November 2026. Program terms change, so confirm the current price and eligibility with the program before enrolling or filling a prescription.

Who this guide is for

If your employer plan covered a GLP-1 for weight loss in 2026, check whether it still does in 2027. In WTW's 2026 Best Practices in Healthcare Survey, released October 28, 2026, the share of employers covering GLP-1s for weight loss fell from 57% to 53% — the first decline in three years.[1] The survey covered 471 US employers with at least 100 employees, fielded June 22 to August 7, 2026.[1] Of the employers that still cover these drugs, 30% are considering eliminating coverage, and 91% of employers that dropped or are considering dropping coverage cited cost.[1]

That leaves more people paying cash in 2027. This guide lays out the two manufacturer self-pay programs side by side, and explains what the January 1, 2027 list-price change does and does not change for cash-pay patients.

What changes on January 1, 2027: the $675 list price

Novo Nordisk announced on February 24, 2026 that, effective January 1, 2027, it will lower the US list price — the wholesale acquisition cost — of Wegovy (semaglutide) injection 2.4 mg and tablets up to 25 mg, Ozempic (semaglutide) injection, and Rybelsus (semaglutide) tablets to $675 a month.[2] For Wegovy, that is about half the current list price of $1,349.02 a month.[2]

The list price is the price Novo charges wholesalers. It is not the price most patients pay at the pharmacy. It matters most for people whose out-of-pocket cost is tied to list price — for example, patients in high-deductible plans who pay list price until the deductible is met, or patients whose coinsurance is a percentage of list price.

The key point for cash-pay patients: Novo says the list-price change does not affect direct-to-patient self-pay prices.[2] If you buy through NovoCare at the self-pay price, the January 1 change does not lower what you pay.

NovoCare self-pay: Wegovy pill and pen

NovoCare is Novo Nordisk's direct-to-patient program. You still need a prescription from a licensed clinician for an FDA-approved use. Prices checked November 2026:[3]

Wegovy form and dose Self-pay price per month
Pill, 1.5 mg $149
Pill, 4 mg $199
Pill, 9 mg or 25 mg $299
Pen, 0.25 mg to 2.4 mg $349
Pen, HD 7.2 mg $399

New patients pay $199 a month for the first two fills of the 0.25 mg and 0.5 mg pen doses, an offer that runs through December 31, 2026. After that, the pen is $349 a month for 0.25 mg to 2.4 mg.[3] A month of the pill is one bottle of 30 tablets.[3]

The pill price rises with dose. The FDA label's standard tablet schedule starts at 1.5 mg for 30 days, then moves to 4 mg and 9 mg in 30-day stages before the recommended 25 mg maintenance dose.[4] This reflects the standard FDA-approved titration schedule. Your prescriber determines your actual dose. Do not adjust your dose without consulting them. At the maintenance dose, the pill costs $299 a month through NovoCare, $50 less than the standard pen at $349 a month.

LillyDirect self-pay: Zepbound

LillyDirect is Eli Lilly's direct-to-patient program for Zepbound (tirzepatide). Prices checked November 2026:[5]

Zepbound dose Self-pay price per month
2.5 mg $299
5 mg $399
7.5 mg to 15 mg $449

The same prices apply to the KwikPen and single-dose vials. The $449 price for 7.5 mg to 15 mg applies when you refill within 45 days through Lilly's Zepbound Journey Program; otherwise the regular price is $499 a month for 7.5 mg and $699 a month for 10 mg, 12.5 mg, or 15 mg.[5] Lilly says it can change or end these terms at any time, so check LillyDirect for the price that applies in 2027 before planning around these figures.[5]

LillyDirect self-pay cannot be used with commercial insurance, Medicare, or Medicaid. The same applies to NovoCare self-pay: these are cash-pay programs for people paying without insurance coverage for the drug.

Get GLP-1 price and coverage changes by email

Self-pay prices, savings cards and insurer coverage changes, checked and explained. One free email a week.

NovoCare vs LillyDirect side by side

NovoCare — Wegovy (semaglutide) LillyDirect — Zepbound (tirzepatide)
Lowest self-pay price $149/month (pill, 1.5 mg) $299/month (2.5 mg)
Maintenance-dose self-pay price $299/month (pill, 25 mg); $349/month (pen, 2.4 mg) $449/month (7.5–15 mg, refill within 45 days)
Form Daily pill or weekly pen Weekly KwikPen or single-dose vials
Introductory offer $199/month for first two pen fills (0.25/0.5 mg), through Dec 31, 2026 None listed; 2.5 mg and 5 mg are the regular prices
Offer terms Pen intro offer ends Dec 31, 2026 Lilly may change terms at any time; $449 requires a refill within 45 days
Jan 1, 2027 list-price change List price falls to $675; self-pay prices unchanged Not part of Novo's change; check Lilly's 2027 pricing

The lowest starting price is the Wegovy pill at $149 a month. The maintenance-dose comparison is closer: $299 a month for the Wegovy pill at 25 mg against $449 a month for Zepbound at 7.5 mg to 15 mg. Dose matters more than the headline starting price, because both programs charge more as the dose rises.

If your coverage just dropped: what to check first

Check your 2027 formulary now, during open enrollment. Survey figures describe employers as a group. Your own plan documents are what count for your coverage. Coverage for type 2 diabetes usually continues even when weight-loss coverage is dropped, so check which indication your prescription is for.

Check whether a savings card applies. Manufacturer savings cards can bring the cost to $25 a month for eligible patients, but they require commercial insurance and do not work for cash-pay patients or with Medicare or Medicaid. See our savings cards comparison.

Check patient assistance programs. Novo Nordisk and the Lilly Cares Foundation provide free medication to qualifying low-income patients without prescription drug coverage. Income limits and covered drugs change, so check each program's current rules. See our patient assistance programs guide.

Check Medicare options if you are on Medicare. The Medicare GLP-1 Bridge program offers a flat $50 a month for eligible Part D beneficiaries for Wegovy, Zepbound (KwikPen), and Foundayo (orforglipron), and runs through December 31, 2027. See our Medicare Bridge guide.

Budget beyond the drug. Prescriber visits, lab monitoring when required, and pharmacy or shipping charges sit on top of the medication price. Telehealth programs often charge $79–$199 a month for the consultation on top of the drug. For a full breakdown, see our GLP-1 cost comparison.

Bottom line

Employer coverage of GLP-1s for weight loss fell from 57% to 53% in WTW's 2026 survey, and 30% of employers that still cover them are considering dropping coverage.[1] For 2027 cash-pay patients, the published manufacturer prices are $149 to $299 a month for the Wegovy pill through NovoCare, $349 a month for the standard Wegovy pen, and $299 to $449 a month for Zepbound through LillyDirect — all checked November 2026.[3][5] Novo's $675 list price from January 1, 2027 helps patients whose costs follow list price, such as high-deductible plans. It does not change self-pay prices.[2]


Prices and program terms can change. This guide is informational and is not medical, insurance, or financial advice. A prescription and clinician's evaluation are required.

Sources

Get GLP-1 price and coverage changes by email

Self-pay prices, savings cards and insurer coverage changes, checked and explained. One free email a week.

We respect your privacy. Unsubscribe anytime.

Next up

A few related reads to keep your momentum.

Related articles

Written by
J
Jeremy H.
GLP-1 Nutrition Researcher

Nutrition researcher and founder of The GLPSpot. Jeremy built this site after watching friends and family struggle with the nutritional challenges of reduced appetite on GLP-1 medications — loss of muscle mass, dehydration, and nutrient deficiencies.

Published:
Medical Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment.